Evidence map›Paper›PMID 40285971›Full record

ArticleAnnals of nuclear medicine2025

Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load.

Ryo Yamakuni, Mitsunari Abe, Naoyuki Ukon, Hiroshi Matsuda, Harumasa Takano, Nobukatsu Sawamoto, Atsushi Shima, Yuhei Mori, Hirofumi Sekino, Shiro Ishii and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Comparison of Amyloid-PET Analysis Software UsingDiagnostics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ryo YamakuniDepartment of Radiology and Nuclear Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan. yamakuni@fmu.ac.jp.ORCID http://orcid.org/0000-0003-0265-5636
Mitsunari AbeIntegrative Brain Imaging Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Naoyuki UkonAdvanced Clinical Research Center, Fukushima Medical University, Fukushima, Japan.
Hiroshi MatsudaDepartment of Bio-Functional Imaging, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Harumasa TakanoIntegrative Brain Imaging Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Nobukatsu SawamotoDepartment of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Atsushi ShimaHuman Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yuhei MoriDepartment of Neuropsychiatry, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hirofumi SekinoDepartment of Radiology and Nuclear Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Shiro IshiiDepartment of Radiology and Nuclear Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Kenji FukushimaDepartment of Radiology and Nuclear Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Toshiki MizunoDepartment of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Jin NarumotoDepartment of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takashi HanakawaDepartment of Integrated Neuroanatomy and Neuroimaging, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hiroshi ItoDepartment of Radiology and Nuclear Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Parkinson’s and Alzheimer’s disease Dimensional Neuroimaging Initiative (PADNI)

Funding

Japan Agency for Medical Research and Development 18dm0307003h0001
6 · The paper itself

Abstract

objectiveTo enhance amyloid-β (Aβ) positron emission tomography (PET) diagnostic accuracy and adjust for tracer differences, the amyloid-β load (Aβ

methodsData from 281 consecutive participants (144 males; mean age, 69.6 years) in the Parkinson's and Alzheimer's Disease Dimensional Neuroimaging Initiative study were analyzed. Initial data, including Aβ PET, structural MRI, and Global Clinical Dementia Rating (G-CDR) scores, were reviewed. CL was calculated using the cerebral cortical and striatum Volume of Interest templates (VOI) and whole cerebellum VOI. Aβ

resultsCL and Aβ

conclusionsThis study demonstrated a high correlation and non-inferiority between CL and Aβ

Indexed as

Amyloid beta-PeptidesPositron-Emission TomographyAgedAged, 80 and overAlzheimer DiseaseFemaleHumansImage Processing, Computer-AssistedMaleMiddle AgedAmyloid beta-PeptidesAlzheimer’s diseaseAmyloidIQAmyloid loadCentiloid scalePositron emission tomography

Identifiers

PMID40285971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.